A phase I study of PGG-glucan in healthy human volunteers
Phase of Trial: Phase I
Latest Information Update: 17 Mar 2017
Price : $35 *
At a glance
- Drugs PGG-glucan (Primary)
- Indications Breast cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Follicular lymphoma; Head and neck cancer; Malignant melanoma; Myelosuppression; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer
- Focus Pharmacodynamics
- 17 Mar 2017 New trial record
- 24 Feb 2017 According to a Biothera media release, results from the study were delivered in a poster presentation at the American Society of Clinical Oncology (ASCO) - Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium.
- 24 Feb 2017 Results published in a Biothera media release.